You have already added 0 works in your ORCID record related to the merged Research product.
Efficacy of alternate day versus daily dosing of rosuvastatin.
Copyright policy )Background Compared with other statins, rosuvastatin has a relatively long half-life, which may allow for the administration of this medication on an alternate day basis. Objective To compare the efficacy of administering rosuvastatin on a daily basis versus on an alternate day basis for the treatment of dyslipidemia. Methods In the present crossover study, 45 patients with documented hypercholesterolemia requiring pharmacotherapy were administered either 20mg of rosuvastatin on alternate days or 10mg of rosuvastatin daily for six weeks. After a four-week washout period, patients were then switched to the other regimen for another six weeks. The primary end point was the percentage reduction of low-density lipoprotein cholesterol (LDL-C). Results LDL-C decreased by 48.5% versus 40.9% with daily and alternate day dosing, respectively. This represented an additional absolute reduction of LDL-C of 7.6% (95% CI 1.8% to 13.4%, P=0.012) with the daily dosing regimen. Both dosing regimens provided similar improvements in high-density lipoprotein cholesterol and triglycerides. Conclusions Compared with alternate day dosing, daily dosing of rosuvastatin provides a statistically significant advantage in LDL-C reduction. However, the alternate day regimen may be a viable option for those patients in whom cost is a limitation to compliance.
Microsoft Academic Graph classification: Regimen Rosuvastatin Calcium Crossover study Dyslipidemia medicine.disease medicine Rosuvastatin medicine.drug Anesthesia Dosing Internal medicine medicine.medical_specialty Endocrinology Clinical endpoint business.industry business Pharmacotherapy
Medical Subject Headings: nutritional and metabolic diseases lipids (amino acids, peptides, and proteins)
Adolescent, Adult, Aged, Aged, 80 and over, Cholesterol, HDL, Cholesterol, LDL, Confidence Intervals, Cross-Over Studies, Drug Administration Schedule, Female, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Male, Middle Aged, Patient Compliance, Pyrimidines, Rosuvastatin Calcium, Sulfonamides, Triglycerides, Young Adult, Letter to the Editor, Clinical Studies, Treatment Outcome, Cardiology and Cardiovascular Medicine
Adolescent, Adult, Aged, Aged, 80 and over, Cholesterol, HDL, Cholesterol, LDL, Confidence Intervals, Cross-Over Studies, Drug Administration Schedule, Female, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Male, Middle Aged, Patient Compliance, Pyrimidines, Rosuvastatin Calcium, Sulfonamides, Triglycerides, Young Adult, Letter to the Editor, Clinical Studies, Treatment Outcome, Cardiology and Cardiovascular Medicine
Microsoft Academic Graph classification: Regimen Rosuvastatin Calcium Crossover study Dyslipidemia medicine.disease medicine Rosuvastatin medicine.drug Anesthesia Dosing Internal medicine medicine.medical_specialty Endocrinology Clinical endpoint business.industry business Pharmacotherapy
Medical Subject Headings: nutritional and metabolic diseases lipids (amino acids, peptides, and proteins)
- Western University Canada
- Kingston General Hospital Canada
- Queen's University Canada
- Western University Canada
- Kingston General Hospital Canada
- Queen's University Canada
Background Compared with other statins, rosuvastatin has a relatively long half-life, which may allow for the administration of this medication on an alternate day basis. Objective To compare the efficacy of administering rosuvastatin on a daily basis versus on an alternate day basis for the treatment of dyslipidemia. Methods In the present crossover study, 45 patients with documented hypercholesterolemia requiring pharmacotherapy were administered either 20mg of rosuvastatin on alternate days or 10mg of rosuvastatin daily for six weeks. After a four-week washout period, patients were then switched to the other regimen for another six weeks. The primary end point was the percentage reduction of low-density lipoprotein cholesterol (LDL-C). Results LDL-C decreased by 48.5% versus 40.9% with daily and alternate day dosing, respectively. This represented an additional absolute reduction of LDL-C of 7.6% (95% CI 1.8% to 13.4%, P=0.012) with the daily dosing regimen. Both dosing regimens provided similar improvements in high-density lipoprotein cholesterol and triglycerides. Conclusions Compared with alternate day dosing, daily dosing of rosuvastatin provides a statistically significant advantage in LDL-C reduction. However, the alternate day regimen may be a viable option for those patients in whom cost is a limitation to compliance.